

# BD Statement On FTC Clearance Of Bard Acquisition

FRANKLIN LAKES, N.J., Dec. 22, 2017 [PRNewswire/](#) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the divestitures of BD's soft tissue core needle biopsy product line and C. R. Bard's Aspira® product line of tunneled home drainage catheters and accessories:

"FTC approval brings us one step closer to full regulatory clearance of the Bard acquisition," said Vincent A. Forlenza, chairman and CEO of BD. "We currently expect that the Bard acquisition will close in December, pending approval by the Ministry of Commerce of the People's Republic of China (MOFCOM) and the satisfaction of customary closing conditions."

## *About BD*

BD is a global medical technology company that is *advancing the world of health* by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit [bd.com](http://bd.com).

## *FORWARD-LOOKING STATEMENTS*

This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to the pending acquisition of Bard by BD that involves substantial risks and uncertainties, including, among other things, risks related to the satisfaction of the conditions to closing the acquisition in the anticipated timeframe or at all. These statements are based on the current expectations of BD management and these statements speak only as of the date of this document. BD undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.

## Contacts:

Troy Kirkpatrick      Monique N. Dolecki

BD Public Relations      BD Investor Relations

858.617.2361      201.847.5378

[troy.kirkpatrick@bd.com](mailto:troy.kirkpatrick@bd.com)      [Monique\\_Dolecki@bd.com](mailto:Monique_Dolecki@bd.com)

View original content with multimedia: <http://www.prnewswire.com/news-releases/bd-statement-on-ftc-clearance-of-bard-acquisition-300575094.html>

SOURCE BD (Becton, Dickinson and Company)

---

<https://news.bd.com/2017-12-22-BD-Statement-On-FTC-Clearance-Of-Bard-Acquisition-1>